SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFis quarterly results beat expectations, with raised full-year guidance and a new 2027 outlook drawing bullish reactions. Traders remain divided over whether the strong report can sustain a rebound or whether the stock will repeat its pattern of fading after earnings.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPals quarterly results and raised full-year earnings outlook are driving attention: traders point to earnings and operating-income beats, while revenue and payment volume fell short of estimates. The stocks decline despite the guidance raise has left the community divided between optimism about the results and frustration over weak growth and the muted market reaction.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcoms $63 billion financing arrangement to supply AI chips and networking equipment to Anthropic is driving attention, with traders viewing it as a sign of future demand. Others question the financing and residual-value risks, and argue the news has not resolved the stocks relative weakness.

United Parcel Service, Inc. is a package delivery company, which engages in the provision of global supply chain management solutions. It operates through the following segments: U.S. Domestic Package and International Package. The U.S. Domestic Package segment includes time-definite delivery of letters, documents, and packages. The International Package segment focuses on delivery and shipments in Europe, Asia, the Indian sub-continent, the Middle East, Africa, Canada, and Latin America. The company was founded by James E. Casey and Claude Ryan on August 28, 1907 and is headquartered in Atlanta, GA.

United Parcel Service, Inc. - Ordinary Shares - Class B

United Parcel Service, Inc.

UPS is drawing attention after third-quarter results beat expectations and management raised its full-year outlook, though traders are debating the muted share-price reaction. Bulls point to a shift toward higher-margin shipments and network efficiencies, while skeptics question whether margins and peak-season execution can sustain the improvement as Amazon volume declines.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Cornings quarterly results modestly topped expectations, while its outlook pointed to continued growth, drawing attention ahead of the earnings reaction. Traders are split on whether the beat and guidance can overcome caution about the stocks history of post-earnings declines and whether strong results were already priced in.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the Advanced Technology Solutions (ATS) and Connectivity and Cloud Solutions (CCS) segments. The ATS segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The CCS segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celesticas stronger-than-expected quarterly results and upbeat 2027 outlook, supported by demand for AI data-center infrastructure, drove the dominant discussion and a sharp post-report rebound after a steep selloff. Traders are divided on whether the growth outlook supports the valuation, citing concerns about margins, cash flow and customer concentration alongside optimism about sustained AI spending.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

Attention centers on the anticipated final analysis of SELLASs Phase 3 REGAL trial of GPS in AML, which is triggered at 80 events; traders are focused on when the milestone and topline results will be disclosed, with ASH as a possible venue for an update. Bulls interpret the prolonged wait as a sign patients may be living longer and speculate about a favorable readout or a buyout, while bears say the delay and company silence raise concerns about the trial and its results.

Royal Caribbean Group is a cruise company, which engages in the ownership and operation of the following global cruise brands: Royal Caribbean International, Celebrity Cruises, and Silversea Cruises. The firm also holds interest in TUI Cruises GmbH, which operates the German brands TUI Cruises and Hapag-Lloyd Cruises. The company was founded by Arne Wilhelmsen in 1968 and is headquartered in Miami, FL.

Royal Caribbean Group

Royal Caribbeans Q3 earnings beat and higher full-year guidance drew attention, while a softer-than-expected Q4 outlook and expenses shifting into the next quarter prompted questions about the durability of the beat. Traders are weighing strong demand and bookings against near-term guidance concerns and debt risks.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is drawing attention after a broad-market bounce, with traders linking the move to optimism around possible Iran de-escalation and strength in AI and semiconductor shares, while watching the Fed and major tech earnings. The reaction is divided: some expect the rally to continue, while others see a fragile, headline-driven bounce and anticipate a fade.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weaker-than-expected Q3 results and another cut to its 2026 outlook, now calling for an adjusted loss, are driving the discussion. Traders are largely concerned about continued declines, weak demand and debt, while some see the selloff as a potential bottom and hope managements conference-call comments offer reassurance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

The average of price targets set by Wall Street analysts indicates a potential upside of 123.4% in Maze Therapeutics, Inc. (MAZE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Twin Moves: VRTX Rises On Kidney Disease Trial Results, MAZE Rallies Harder  

Equity

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.


Maze Therapeutics Chief Medical Officer Dumps Entire Direct Stake in the Company for $255,000

Key PointsChief Medical Officer Harold Bernstein sold 9,705 shares for ~$255,000 on September 4, 2026...

Can Maze Therapeutics, Inc. (MAZE) Climb 120.48% to Reach the Level Wall Street Analysts Expect?

The consensus price target hints at a 120.5% upside potential for Maze Therapeutics, Inc. (MAZE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

What Does the Maze Therapeutics CEO's Sale of Nearly 30,000 Shares Mean for Investors?

Key PointsCEO Jason Coloma sold 27,858 shares for a total value of approximately $725,000 across June 22 and June 23, 2026...

Maze Therapeutics' CEO Sold Over 30,000 Company Shares. What Does That Mean for Investors?

Key PointsCEO Jason Coloma sold 32,564 shares in May for a total transaction value of approximately $847,000, at a weighted average price around $26.01 per share...

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares

Maze Therapeutics Stock Still Up 180% After March Tumble. One Fund Just Disclosed Selling $3 Million in Shares...

Maze Therapeutics, Inc. (MAZE) Reports Q1 Loss, Beats Revenue Estimates

Maze Therapeutics, Inc. (MAZE) delivered earnings and revenue surprises of -5.07% and +23.08%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Rating of "Buy" by Analysts

Shares of Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) have been given a consensus rating of "Buy" by the eleven brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a buy rating and two ha...

Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes the Compass platform, which allows it to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 29, 2017 and is headquartered in San Francisco, CA.

Maze Therapeutics Inc.

Bearish Sentiment

<ul class="summary-bullets"><li>In people with modest proteinuria, albumin in the urine fell 42.7% from baseline, and total protein fell 44.7% in the study.&nbsp;</li><li>A second group — people who also have type 2 diabetes — saw a smaller drop: 17.3% for albumin and 25.4% for total protein.</li><li>Truist called the data a validation of APOL1 inhibition in a potential market of more than 100,000 patients and said the opportunity is large enough to support blockbuster sales for Maze’s MZE829 even if it only matches inaxaplin.</li></ul><p><br>Shares of Vertex Pharmaceuticals (VRTX) rose 3% on Tuesday after the company said its experimental pill inaxaplin cut protein leakage into urine in a study in two extra groups of patients with APOL1-mediated kidney disease (AMKD), a genetic condition with no approved treatments.</p><p>Rival Maze Therapeutics (MAZE), which is developing its own drug for the condition called MZE829, jumped more sharply, by about 25%, on the read-through.</p><h2 class="st-heading-2">Broader Patients, Similar Signal</h2><p>The mid-stage AMPLIFIED study tested a once-daily 45 mg dose of inaxaplin for 13 weeks on top of optimized standard care. In people with modest proteinuria, urinary albumin fell 42.7% from baseline, and total protein fell 44.7%. That matched an earlier mid-stage study in patients with a scarring form of the disease known as Focal Segmental Glomerulosclerosis (FSGS). Most people in the new modest-proteinuria group did not have an FSGS diagnosis.</p><p>A second group — people who also have type 2 diabetes — saw a smaller drop: 17.3% for albumin and 25.4% for total protein. Vertex called that effect encouraging but more modest. The drug was generally well tolerated. No serious side effects were tied to inaxaplin; headache was the most common complaint.</p><p>AMKD is a rapidly progressing disease caused by two variants in the APOL1 gene and occurs mainly in people of African ancestry. Vertex estimates it affects about 150,000 people in the United States and Europe. Left untreated, it can lead to dialysis, transplant, or death.</p><h2 class="st-heading-2">Pivotal Study Now Fully Enrolled</h2><p>Vertex also said it has finished enrollment in AMPLITUDE, the larger trial in patients with more severe proteinuria and no other major kidney-damaging conditions. An interim look is due in early 2027 and, if positive, could support a U.S. accelerated-approval filing. The company plans to discuss the AMPLIFIED results with regulators alongside that program.</p><p>Chief medical officer Carmen Bozic said the findings add to evidence that inaxaplin could become a first- and best-in-class therapy aimed at the disease’s root cause.</p><h2 class="st-heading-2">Analysts See A Bigger Market — And A Lift For Maze</h2><p>Truist analyst Danielle Brill called the data a meaningful validation of APOL1 inhibition in classic AMKD and estimated an addressable population of more than 100,000 patients. Truist sees “a significant positive readthrough” for Maze. While it is too early to compare the two drugs, the firm said the opportunity is large enough to support blockbuster sales for MZE829 even if efficacy and safety prove only comparable to inaxaplin. Truist rates Maze a Buy with a $64 price target. The new price target implies a potential upside of about 186% from the stock’s last closing price on Monday.</p><h2 class="st-heading-2">How Did VRTX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around VRTX stock stayed in ‘bearish’ territory over the past 24 hours, while message volume stayed ‘low.’</p><p>Meanwhile, sentiment around MAZE jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while retail chatter jumped to ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/VRTX">VRTX stock</a> is up about 15% year to date. <a href="https://stocktwits.com/symbol/MAZE">MAZE </a>is down about 35% over the same stretch, leaving Tuesday’s pop against a steep 2026 drawdown.</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/michael-burry-memory-stocks-thesis-gets-fresh-support-from-acer-ceo-supply-warning/cZMPMm7RB7b">Michael Burry’s Memory Stocks Thesis Gets Fresh Support From Acer CEO’s Supply Warning</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration, Vertex Pharmaceuticals' logo is displayed on a smartphone screen in front of a stock chart. (Photo illustration by Cheng Xin/Getty Images)

Vertex on Tuesday announced results from the mid-stage trial of its experimental pill, inaxaplin, in two groups of patients with APOL1-mediated kidney disease.

Vertex Pharmaceuticals, Inc.

$HOOD (Tuesday afternoon)

$MSFT (Wednesday afternoon)

$GOOGL (Wednesday afternoon)

$AMZN (Thursday afternoon)

Which earnings release are you most excited for this week?

Drop a comment for other tickers.

Current Price	$31.07
Prev Close	$31.01
Open	$30.93
Dividend Yield	0.00%
50-Day Moving Average	$27.27
Beta	0.94
Avg. Volume	842,768.05
PE Ratio	-12.26

52-Week High	$53.65
52-Week Low	$21.95
Market Capitalization	$1.73B
EPS (Annual)	-$2.66
Price to Book	3.81
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

MAZE Fundamentals